Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/01/24
Merck's fourth-quarter results top estimates, fueled by key cancer drugs and vaccinesMarket Watch • 02/01/24
Merck Reports A Surprise Profit As Keytruda Sales Continue On Their WarpathInvestors Business Daily • 02/01/24
Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 01/29/24
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugsCNBC • 01/28/24
Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following NephrectomyBusiness Wire • 01/27/24
Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After SurgeryBusiness Wire • 01/26/24
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 01/25/24
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1Business Wire • 01/19/24